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Abstract
Intestinal transplantation (ITx) has evolved in the past few decades moving from an 
experimental procedure to a life-changing modality for patients suffering from intestinal 
failure (IF). It is particularly for those with complications as a consequence of parenteral 
nutrition and/or who have a high risk of dying due to their underlying disease. In addi-
tion to this, intestinal transplantation is also increasingly considered for the treatment of 
conventionally unresectable abdominal tumors. With advancements in immunosuppres-
sive drugs, induction regimens, standardization of surgical techniques and improved 
postoperative care, survival is increasing. The ultimate goal for intestinal transplantation 
would be to become as good and safe as total parenteral nutrition (TPN) and as such, it 
could become a viable first-line option of intestinal failure.
Keywords: intestinal failure, parenteral nutrition, multivisceral, intestine, liver, 
immunosuppression, intestinal transplant
1. History
Lillehei was the first to report an experimental isolated intestinal canine model in 1959 and 
Starzl reported the first multivisceral experimental canine model in 1960 [1, 2]. The first 
attempt in humans has been attributed to Deterling in Boston in 1964 [unpublished], whereas 
the first official report of human intestinal transplant was made by Lillehei in 1967 [1]. It 
should be noted that the first successful series were reported in the 1990s, coinciding with the 
introduction of more effective immunosuppression. The first attempts of intestinal transplan-
tation (ITx) in the 1970s were largely disappointing because of high incidence of rejection of 
small bowel allografts, sepsis and technical complications [3]. The introduction of tacrolimus 
[4] revolutionized interest in ITx. The superior clinical outcomes from tacrolimus across a 
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variety of organ transplantation compared with cyclosporine set the momentum for ITx as a 
life-changing therapy for patients with irreversible intestinal failure (IF) [5, 6].
Over the past 30 years, there has been a gradual increase in ITx cases, with nearly 2900 ITx 
cases performed worldwide, although there has been a decline in recent years [7]. This change 
could be attributed to the formation of specialized IF units to prevent and manage intesti-
nal failure-associated liver disease (IFALD) [8]. Other possible factors include: inadequate 
reimbursement rates below the cost of performing the transplant; the extensive infrastructure 
demands required to address the frequent social problems of IF patients; concern over the 
narrow risk-benefit ratio for ITx in an era of improving outcomes with long-term total par-
enteral nutrition (TPN) for selected diseases [9] and/or the limited availability of experienced 
personnel to fill key positions. Finally, some transplant centers may be more willing to judi-
ciously offer isolated liver transplants to patients with the short bowel syndrome and IFALD 
who have the potential for further intestinal adaptation [10, 11].
2. Indications
IF is characterized by the inability to maintain protein energy, fluid, electrolyte or micronutrient 
balance due to gastrointestinal disease. If the patient does not receive parenteral nutrition or 
become a recipient of an intestinal transplant, IF ultimately leads to malnutrition and even death.
The leading causes of IF differ between pediatric and adult populations (Table 1).
TPN is the current standard of care for patients with IF. Nevertheless, as survival following 
ITx improves, it is anticipated that ITx will become a valid alternative to total parental nutri-
tion. However, because of significant complications that can arise from surgery and long-term 
use of immunosuppressive therapy, strict eligibility criteria exist to ensure appropriate patient 
selection.
Paediatric Adult
Intestinal atresia Crohn’s disease
Gastroschisis Superior mesenteric artery thrombosis
Crohn’s disease Superior mesenteric vein thrombosis
Microvillus involution disease Trauma
Necrotizing enterocolitis Desmoid tumour
Midgut volvulus Volvulus
Chronic intestinal pseudo-obstruction Pseudo-obstruction
Massive resection secondary to tumour Massive resection secondary to tumour
Hirschsprung disease Radiation enteritis
Table 1. Leading causes for intestinal transplantation in paediatric and adult populations.
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Short bowel syndrome caused by surgical removal is the leading cause of IF (68%). As an 
early alternative to transplantation or total parenteral nutrition (TPN) for patients with short 
bowel syndrome, surgical bowel lengthening without transplant may be attempted. This 
requires the serial transverse enteroplasty (STEP) or longitudinal intestinal lengthening 
and tailoring (LILT) procedures. STEP and LILT are particularly successful in patients with 
decreased transit times and dilated bowel. These procedures lengthen the small bowel while 
keeping the total surface area the same. Bowel is either split lengthwise or cut obliquely at 
multiple points. This will lengthen the bowel and shrink the luminal diameter [12]. If suc-
cessful, this may reduce the amount of TPN required, or negate its use altogether. If patients 
are not acceptable candidates for STEP or LILT, sometimes a reversal of small bowel direc-
tion may effectively increase transit times. If none of these operations are successful, the 
standard of care is TPN.
Currently, ITx has been mainly performed in patients who developed life-threatening com-
plications attributed to IF and/or long-term TPN. In 2000, Medicare defined failure of TPN 
as impending or overt liver failure (elevated serum bilirubin and/or liver enzymes, spleno-
megaly, thrombocytopenia, gastroesophageal varices, coagulopathy, stomal bleeding, hepatic 
fibrosis or cirrhosis), thrombosis of two or more central veins, frequent and severe central 
venous catheter (CVC)-related sepsis and frequent severe dehydration [13]. In addition, 
other conditions associated with early death despite optimal TPN, such as congenital muco-
sal disorders and ultra-short bowel syndrome, are also included as per American Society of 
Transplantation guidelines [14].
The European guidelines recommend TPN as primary treatment for patients with IF, with 
early referral to specialist centers for optimal rehabilitative therapy and timely assessment 
of suitability for ITx. It recommends assessment for candidacy for transplantation for the 
presence of one or more indications parallel to American guidelines (failure of TPN, high 
risk of death attributable to underlying disease and IF with high morbidity or low accep-
tance of TPN) resulting in rates of transplant of 62, 26 and 12%, respectively [15]. Because 
of a statistically significant increased risk of death on TPN from liver failure due to IFALD 
and invasive intra-abdominal desmoids, direct referral for ITx should be considered [16]. 
IFALD is partly caused by omega-6 fatty acids in TPN formulas, which can be synthesized 
into inflammatory molecules. IFALD can range from steatohepatitis, cholestasis or hepatic 
fibrosis to end-stage liver disease. Children are more likely to have cholestatic liver dis-
ease than steatohepatitis [17]. Severe liver injury has been reported in as many as 50% of 
patients with IF who receive TPN for longer than 5 years; this is typically fatal. If patients 
have life-threatening infections, IFALD, or lose their venous access, 1-year mortality is 
70% without ITx [18]. Conversely, patients with CVC-related complications or ultra-short 
bowel syndrome did not have an increased risk of death on TPN and no patients consid-
ered to be an ITx candidate with poor quality of life (QoL) or chronic dehydration actually 
died while remaining on TPN. This notable finding forms the basis of non-indications in 
previous European guidelines [19]. Despite very limited evidence exploring the role of 
quality of life (QoL) as an indicator for ITx, this holistic aspect may also be factored in the 
decision-making process [20] (Table 2).
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3. Contraindications
The contraindications of intestinal transplantation are the same as for all other transplants 
and are frequently reassessed. These include:
1. significant comorbidities;
2. active uncontrolled infections or malignancies that are not totally resectable during the 
transplant process;
3. psychosocial factors (e.g. lack of post-operative support network);
4. anatomical challenges that can prove the operation high risk such as inferior vena cava 
(IVC) and portal vein (PV) thrombosis. Previous laparotomies can also complicate the op-
eration significantly; and
5. opiate dependence is very common and rehabilitation should be considered early.
4. Types of intestinal transplant
The choice of transplant type depends on the underlying cause of IF, quality of native organs, 
state of liver disease (if present) and history of previous abdominal surgeries. The main types 
of ITx are:
North America Europe
Failure of TPN
Impending or overt liver failure
Central venous thrombosis of 2 central veins
Frequent and severe central venous catheter-related 
sepsis
Frequent episodes of severe dehydration despite 
intravenous fluids in addition to TPN
Impending or overt liver failure due to IFALD-related liver 
failure
High risk of death attributable to underlying disease CVC-related multiple venous thrombosis (in appropriately 
selected patients)
Intra-abdominal invasive desmoids tumour Intra-abdominal desmoids
Intestinal failure with high morbidity and low 
acceptance of TPN
Individual case by case decision for patients with IF with 
high morbidity or low acceptance of TPN
Congenital mucosal disorders
Ultra-short bowel syndrome (<10 cm in infants, <20 cm 
in adults)
Need for frequent hospitalization, narcotic addiction 
or inability to function
Patient’s unwillingness to accept long-term TPN
Table 2. Intestinal transplantation guidelines.
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1. Small bowel transplant only (SBTx) (Figure 1): recommended for people with IF who have 
not developed liver disease. The arterial supply to the allograft is secured with anastomo-
sis between the donor’s superior mesenteric artery (SMA) and the recipient’s infrarenal 
aorta; venous drainage is either onto the IVC or the recipient’s portal vein (PV) or superior 
mesenteric vein (SMV) at the root of the mesentery.
2. Liver and small bowel transplant (SBLTx) (Figure 2): recommended for people with IF 
who also have advanced liver disease and extensive portomesenteric venous thrombosis 
precluding liver transplantation alone. The inclusion of a liver graft in combined liver-
small bowel transplant has been associated with improved survival rates [21].
3. Multivisceral transplant (MVTx) (Figure 3): recommended for people with multiple organ 
failure and involves transplanting the stomach, pancreaticoduodenal complex, liver and 
small bowel.
4. Modified multivisceral transplant (MMVTx) (Figure 4): recommended for people with 
multiple organ failure and involves transplanting the stomach, pancreaticoduodenal com-
plex and small bowel. The difference with the previous type is the exclusion of the liver. 
It is usually performed in patients with preserved liver function and coexisting pancreatic 
insufficiency such as patients with chronic pancreatitis, type I diabetes mellitus or cystic 
fibrosis, patients with intestinal dysmotility with concomitant severe gastroparesis and 
in cases with tumor involvement of the mesentery or the duodenum (e.g. in Gardner’s 
syndrome) [22].
Figure 1. Small bowel transplant (SBTx).
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Figure 3. Multivisceral transplant (MVTx).
Figure 2. Liver and small bowel transplant (SBLTx).
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In all the above ITx types, the right hemicolon can be included depending on the patient’s 
native anatomy. Since 2000, there has been a sixfold increase in the inclusion of a colon seg-
ment resulting in a current inclusion rate of 30% [7]. The registry analysis has shown that 
inclusion of the colon did not adversely affect survival and recipients with a colon segment 
had a 5% higher rate of independence from supplemental parenteral nutrition (PN), as the 
retention of the ileocecal valve and the right colon enhance gut function through better fluid 
absorption and uptake of free fatty acids [23].
It’s sometimes possible to carry out a small bowel transplant using a section of bowel donated 
by a living family member and the first standardized technique was reported by Gruessner 
and Sharp [24].
Because of previous surgery resulting in loss of abdominal wall domain and integrity, patients 
undergoing ITx face a problem with primary abdominal wall closure [25]. Surgical techniques 
such as reduction of the liver portion (left or right lobe) within the composite allograft [26], 
transplantation of composite abdominal wall tissue graft (Figure 5) [27, 28], the use of vascu-
larized rectus sheath [29] and non-vascularized abdominal rectus fascia [30] have revolution-
ized abdominal wall reconstruction.
Figure 4. Modified multivisceral transplant (MMVTx).
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5. Recipient assessment
The assessment of a potential intestinal transplant recipient is robust and rigorous and needs 
to be done by a multidisciplinary team. This involves transplant surgery, gastroenterology, 
nutritional services, anesthesia, psychiatry and social work. However, due to the frequently 
pre-existing multiple comorbidities, consultation with other specialties may be required. 
Every assessment is ‘tailor-made’.
Laboratory studies always include: full blood count (FBC), electrolytes and renal function, 
coagulation profile, ABO blood group, human leukocyte antigen (HLA) typing, panel- 
reactive antibody status, HIV and hepatitis B and C virus screening, cytomegalovirus (CMV) 
and Epstein-Barr virus (EBV) screening.
Liver biopsy is indicated, if liver disease is suspected. The native intestine should be assessed 
both by imaging and endoscopy.
Figure 5. Abdominal wall transplant.
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Vascular access is of utmost importance and is assessed by magnetic resonance or com-
puted tomography venogram. Securing upper-body vascular access is mandatory in cases 
where IVC occlusion is anticipated. Many patients will have central venous stenosis or 
obstruction and will mandate interventional radiology and/or vascular reconstruction 
before listing.
Manometry of the esophagus, stomach and rectum should be considered in patients with 
dysmotility disorders.
While on the waiting list, patients should be frequently reassessed, with specific attention 
given to any change in medical status, deterioration in liver function or vascular access.
6. Surgical technique
6.1. Intestinal retrieval
• Wide access to the abdominal cavity is needed and can be achieved via a midline incision 
from the suprasternal notch down to the symphysis pubis.
• The ascending colon and hepatic flexure are mobilized by using right-sided medial visceral 
rotation (Cattel-Braasch maneuver) that will expose the third and fourth portions of the 
duodenum.
• First, achieve control of the right common iliac artery or the distal abdominal aorta, which 
need to be mobilized for subsequent insertion of the infusion cannula.
• The structures of the hepatoduodenal ligament will have to be identified and slung for 
small bowel alone or modified multivisceral transplants.
• Depending on the type of transplant, sling the esophagus, the antrum or proximal jejunum.
• In case of MMVTx, the celiac axis has to be retrieved along with the left gastric and splenic 
arteries. This should be discussed with the liver implanting team in case of a left aberrant 
artery.
• Transect the gastrocolic ligament and, in case of large bowel retrieval, identify the middle 
colic vessels. Mark the transverse colon just distal to the vessels for the insertion of the gastro-
intestinal anastomosis (GIA) stapler. For small bowel, sling the ileum near the ileocecal valve.
• Expose the mesenteric root, abdominal aorta and infrahepatic IVC, including entry of the 
renal veins.
• If the pancreas is to be retrieved, the splenic flexure, spleen, and body and tail of pancreas 
are mobilized to allow adequate subsequent cooling of the pancreas.
• Perform proximal control for supraceliac cross-clamping, either above or below the dia-
phragm, depending on the presence of a cardiothoracic team.
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• Cross-clamping of the supraceliac aorta is performed simultaneously with or immediately 
following venting of the IVC or atrium and cold perfusion is commenced.
• In situ cooling of abdominal organs, and exsanguination before removing the organs to the 
back table for preparation.
• University of Wisconsin (UW) Universal Organ Preservation solution for both in situ flush-
ing and cold storage is most frequently used.
• Retrieve iliac, brachiocephalic and/or carotid arteries and veins as potential vascular grafts.
6.2. Back-table preparation of organs
Intestinal grafts require minimal back table; however, this depends on the retrieval technique 
and the extension of the allograft. Most commonly, back table involves to identify and tie the 
lymphatics. If the pancreas is retrieved along with a small bowel only graft, then it has to be 
removed/sacrificed on the back table.
6.3. Recipient operation
• Implantation begins commonly with adhesiolysis, as adhesions are usually abundant sec-
ondary to previous surgeries.
• Depending on the type of transplant, the aorta and IVC or SMA and SMV/PV are dissected 
and mobilized for the vascular anastomosis.
• The proximal and distal ends of the native digestive track are identified and dissected.
• Venous anastomosis to the graft is frequently performed to the recipient cava. However, 
when possible, venous anastomosis to the portal system is preferred.
• Arterial anastomosis is performed to the abdominal aorta via arterial jump graft.
• After reperfusion of the graft and careful hemostasis, the proximal and distal ends of the 
intestinal graft are anastomosed to the proximal and distal ends of the native digestive 
track. In some cases, the distal end is brought out as a permanent stoma.
• Most centers bring out a temporary stoma by utilizing various techniques (e.g. Bishop 
Koop), for post-operative endoscopic surveillance. This stoma is usually reversed in 
6–12 months.
• Closure of the abdominal wall can be very challenging and should not be attempted under 
tension; if this is the case, keeping the abdominal wall open and planning for a sequential 
closing is preferable. Some centers are routinely performing abdominal wall transplanta-
tion from the same deceased donor in order to achieve closure.
7. Postoperative considerations
Patients are monitored in intensive therapy unit (ITU) post-operatively. It is common prac-
tice to administer broad-spectrum intravenous antibiotics and antifungals for 5–7 days post 
transplantation. Blood tests are sent daily and as well as arterial/venous blood gases to check 
bleeding and homeostasis.
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Stoma output is monitored daily and will indicate the appropriate timing to resume enteral 
feeding via nasogastric tube or jejunostomy/gastrostomy. Some centers start elemental enteral 
feeding very early and gradually increase volumes depending on nasogastric tube aspirates. 
TPN is maintained for at least 2 weeks and can be discontinued once enteral nutrition is 
sufficient. Chyle leak can often be seen post-operatively due to the severed intestinal graft 
lymphatics. A no-fat or low-fat diet (<10 g/day) can be initiated as a first measure. Absorption 
of long-chain triglycerides, depends on lymphatic drainage, whereas medium-chain triglyc-
erides are directly absorbed into the portal circulation.
Antiviral prophylaxis with intravenous ganciclovir (5 mg/kg OD) is common practice and 
regular CMV polymerase chain reaction (PCR) DNA tests are sent for monitoring. Oral val-
ganciclovir is usually prescribed for 1-year post transplantation (900 mg OD). Epstein-Barr 
virus (EBV) is also monitored regularly by PCR. Trimethoprim-sulfamethoxazole is com-
monly used to prevent pneumocystis pneumonia for 1-year post operatively. Routine cultures 
are sent from all lines and most centers perform regular intestinal transplant endoscopies and 
biopsies via the stoma.
Oral medication is generally avoided in the early phase due to the unpredictable absorption 
and thus, bioavailability. Tacrolimus can be given sublingually and regular trough levels are 
sent for confirmation.
Plasma citrulline levels have emerged as a measure for overall for intestinal health as it is an 
indicator of enterocyte mass. However, compromised renal function is an important factor 
when considering plasma citrulline levels as a marker of intestinal failure as this potentially 
can increase circulating citrulline values [31]. Reduced citrulline levels can indicate the need 
for urgent investigations and also, commencement of TPN.
8. Immunosuppression
The intestine is the largest lymphoid organ in the body and hence, appropriate immunosup-
pression has been a real challenge. The lack of effective immunosuppressive agents hampered 
the first attempts of ITx in the 1960s. Over the years, advances in immunosuppression have 
transformed ITx with the intent of attenuating the intestinal allograft immunity and shifting 
it to a tolerogenic status [32].
Induction strategies to minimize rejection by reducing the recipient’s T-cell load were imple-
mented, initially with cyclophosphamide induction therapy, which was later replaced by 
daclizumab, an interleukin-2 receptor antagonist (IL2RA) [33]. Basiliximab, another IL2RA, in 
addition to tacrolimus and prednisone immunosuppression has also been utilized and shown 
to decrease the incidence of acute rejection [34, 35].
Alemtuzumab induction is becoming increasingly popular and Lauro et al. [36] reported sig-
nificantly less early rejection episodes, with no sepsis implications. The use of Basiliximab 
monthly as part of maintenance immunosuppression has been associated with a decrease in 
acute rejection in liver-excluding transplants [37].
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Immunosuppression regimen varies, with several protocols having been reported: Tacrolimus 
and steroids (35.8%) followed by tacrolimus, mycophenolate and steroids (18.7%), tacrolimus 
and mycophenolate without steroids in 15.4% of cases and tacrolimus alone in 13.8% of cases [38].
Target trough levels of tacrolimus vary between centers. Pittsburgh has reported target levels 
between 10 and 15 ng/ml in the first 3 months and thereafter 5–10 ng/ml [39]. Tacrolimus with 
low-dose steroids remains the most effective and durable long-term combination therapy [21] 
and is the most common maintenance immunosuppressive regimen [7].
Sirolimus, a rapamycin inhibitor, has been shown as a useful adjunct to tacrolimus in the 
presence of nephrotoxicity or rejection [40]. However, it carries the disadvantage of severe 
debilitating oromucosal ulceration. Azathioprine and mycophenolate mofetil have also been 
used as adjunctive immunosuppressive therapies [33]. Mycophenolate mofetil, however, 
causes symptomatic diarrhea (increased stoma output) and microscopically evident apop-
tosis in approximately 40% of solid organ transplant recipients, which could regrettably be 
mistaken for rejection [41].
9. Complications
Complications following ITx may result in graft failure and invariably death. Patients under-
going ITx have a higher incidence of life-threatening infectious complications than other trans-
plant recipients. This is due to the high bacterial load of the transplanted graft [42]. Therefore, 
any breach to the intestinal transplant mucosal barrier can lead to bacterial translocation.
Graft loss would need TPN resuming and consideration of re-transplantation, which has a 
lower rate of success compared with the initial transplantation [43]. Common causes of graft 
loss include allograft rejection, infection, GVHD and post-transplant lymphoproliferative dis-
order (PTLD) [33].
9.1. Acute rejection
Allograft rejection has always been one of the most significant challenges to long-term graft 
and patient survival and can occur either as acute (commonly in the early phase, though can 
occur late) or chronic (typically taking months to years). Rejection can occur at any time but 
is most common in the first year, particularly the first 6 months. It affects 45% of ITx patients 
within the first post-transplant year, with implications on graft survival [7] and is mostly 
characterized by T-cell response to donor antigens.
Acute rejection should be suspected in all cases of bowel dysfunction (increased stoma out-
put) and symptoms include fever, vomiting, abdominal pain and distension. Diagnosing 
acute rejection is always challenging and requires a combination of clinical, endoscopic and 
histopathological investigations. Intestinal allograft endoscopy and biopsies is the gold stan-
dard. However, diagnosis can be difficult to establish because of the patchy nature of rejec-
tion. Not to mention, that it is not always easy to differentiate between rejection and infection.
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Most centers will endeavor to perform early, frequent endoscopies because of high preva-
lence of acute rejection in the early post transplantation phase [21] and then continue with 
regular endoscopies as part of their surveillance protocol [44].
The Oxford group, who is utilizing vascularized composite allograft (VCA) transplants from 
the same donor [45], is now mostly relying on the VCA as a surrogate marker for rejection and 
is not strictly adherent to early, intensive intestinal biopsy protocols [46]. They have reported 
that the VCA can provide lead time (about 7 days) before the onset of bowel dysfunction and 
this could be proven as a unique prognostic tool [45].
Rejection episodes are usually treated with pulses of methylprednisolone, and in resistant 
cases, thymoglobulin [32] or alemtuzumab [46].
A recent case series reported good outcomes in ITx of positive cross-match patients with only 
one patient developing acute rejection, with the use of intravenous immunoglobulin (IVIG) 
and rituximab [47]. Bortezomib, a proteasome inhibitor, has also been recently shown to be 
effective against donor-specific antibody (DSA)-related rejection [48]. Recently, Eculizumab, a 
monoclonal antibody that inhibits complement factor 5a, was shown to be effective in main-
taining a 2-year rejection-free period in a highly sensitized patient [49]; however, high costs 
make this approach prohibitive for general use.
As mentioned before, biomarkers such as citrulline have gained interest in recent years. The 
prospective cohort study by Hibi et al. [50] reported excellent negative predictive value (range 
93–99%) for citrulline levels as exclusionary marker for all types of acute rejection (cut-off 
point, 20 mmol/l) and moderate or severe acute cellular rejection (cut-off point, 10 mmol/l). 
Another study by the Bologna group [51] showed that citrulline sensitivity and specificity in 
detecting acute rejection, when adjusted for chronic renal failure, almost doubled the sensitiv-
ity of citrulline as a non-invasive marker of acute rejection in ITx. In general, citrulline can act 
as an exclusionary tool, as high levels are unlikely to be found in intestinal allograft rejection.
Recently, a large series evaluating video capsule endoscopy has shown to be potentially use-
ful in the diagnostic management of patients with ITx [52]. Other non-invasive predictors of 
rejection include a recent retrospective study that revealed low insulin-like growth factor-1 
and high calprotectin levels during malnutrition states post-ITx, and these findings should 
prompt the clinicians to investigate for acute rejection or infection [53]. Circulating apoptotic 
T cells following Caspase 3 activation may be a non-invasive marker for patients who are less 
likely to have rejection episodes than those who have lower levels [54].
9.2. Chronic rejection
Chronic rejection is diagnosed histologically with the identification of an obliterative arteri-
opathy in medium-sized vessels in the serosal layer with diffuse concentric intimal thicken-
ing [55]. This necessitates full-thickness biopsy and makes diagnosis challenging. Chronic 
rejection is clinically associated with diarrhea, ulceration, focal loss of mucosal folds, mural 
thickening and pruning of mesenteric artery arcades [55]. Surgery in such a hostile environ-
ment may lead to unwanted enterotomies and fistulae. Re-transplantation should therefore 
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be considered. Evisceration is a potential life-saving option for ITx patients who developed 
severe rejection, and has similar survival rates with patients who underwent simultaneous 
enterectomy with re-transplantation; however, high sensitization may prevent re-transplan-
tation [56].
9.3. Donor-specific antibodies
Preformed and de-novo DSAs have been associated with acute rejection and may be impli-
cated in chronic rejection and graft loss [46, 57]. Five-year graft survival of less than 30% 
was noted in ITx patients who developed de-novo DSA, whereas survival rates of more than 
80% were observed in recipients without DSA [44]. Yet, others have not found a statistically 
significant trend towards worsening outcomes [58] between those with or without de-novo 
DSA formation.
9.4. Infection
The use of immunosuppression in ITx poses a significant risk of infection and, historically, 
high levels of immunosuppressants have been utilized in ITx. Sepsis remains the most com-
mon cause of death and graft failure, accounting for over 50% of cases [7]. Bacterial infections 
are common in the early phase post-ITx and have a significant impact on patient survival. 
Invasive candidiasis has been reported as the commonest fungal infection [59].
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) viraemias are common and can be 
implicated in acute and chronic rejection as well as PTLD [60, 61]. CMV status is vital to 
anticipate the risk of developing de-novo infection in a non-infected recipient from the donor 
and through reactivation of a latent infection. CMV prophylaxis with oral valganciclovir is 
often continued for 1 year following ITx [62]. Most programs would not accept CMV-positive 
donors for CMV-negative recipients as this is high risk and should be avoided [63]. Last but 
not least, it has been demonstrated that isolated graft CMV disease without overt CMV virae-
mia can indeed occur [64].
9.5. Post-transplant lymphoproliferative disorder
In the updated 2016 WHO lymphoma classification, PTLD has been sub-classified as plasma-
cytic hyperplasia PTLD, infectious mononucleosis PTLD, florid follicular hyperplasia PTLD, 
polymorphic PTLD, monomorphic PTLD and classical Hodgkin lymphoma PTLD [65]. PTLD 
following SOT occurs in up to 20% with the highest incidence in intestinal and multi-organ 
transplants (5–20%), followed by lung and heart transplants (2–10%) and then by renal and 
liver transplants [66].
About 70% of cases of PTLD are associated with Epstein-Barr virus (EBV), especially in cases 
which occur early after transplantation. Pathogenesis of the disease is linked to EBV prolifera-
tion in the setting of chronic immunosuppression leading to an inhibition of T-cells immune 
function. However, in 30% of EBV-negative PTLD patients, pathogenesis is not clearly under-
stood [67].
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It is believed that in ITx, the lymphatic-rich intestinal allografts in combination with sple-
nectomy and immunosuppression pose an increased risk for PTLD [68]. It has been reported 
that the presence of PTLD has significantly reduced patient survival within the first post-
transplant year [69]. PTLD is treated with immunosuppression reduction and rituximab con-
taining chemotherapy regimes in the presence of CD20 positive cases [70].
9.6. Graft versus host disease
The small intestine has abundant lymphoid cells that can mount an immunologic response to 
the host (i.e. a graft versus host disease [GVHD]) reaction. GVHD occurs in 5–7% of intestinal 
transplants, compared to 1% for solid organ transplants, and risk factors include younger age, 
MVTx recipients and intra-operative splenectomy [71]. It is more common in intestinal trans-
plants due to the large volume of lymphatic tissue that is transplanted along with the graft. 
GVHD diagnosis is allegedly difficult to establish and patients usually present 1–8 weeks 
after transplantation with skin rash, ulceration of oral mucosa, diarrhea, lymphadenopathy 
or native liver dysfunction. Diagnosis is confirmed by skin or bowel biopsy.
Treatment strategies vary and most frequently involve tacrolimus, high-dose steroids or 
anti-thymocyte globulin (ATG) [71].
9.7. Renal dysfunction
Renal dysfunction is invariably seen post ITx due to a combination of high-dose tacrolimus 
therapy [72] and dehydration episodes, especially in the presence of stomas. The incidence of 
stage 4 or 5 CKD is 21.3% in patients with ITx [73] and approximately 9% of ITx patients will 
receive renal replacement therapy by a median of 7.4 years [74].
10. Graft and patient survival
Patient survival has been steadily improving because of improved first-year graft survival [7]. 
Graft survival has been reported for 1, 5 and 10 years at 74, 42 and 26%, respectively (SBTx); 
70, 50 and 40% (MVTx); 61, 46 and 40% (SBLTx); overall patient survival was 76, 56 and 43%, 
respectively. Studies evaluating 1-year and 5-year patient survival rates at various transplant 
centers revealed comparable results [75, 76].
Patients on TPN have 1-year, 5-year, 10-year and 20-year survival of 91–93, 70–71, 55–59 and 
28%, respectively, following IF commencement [77]. It should be noted, that 11–15% of deaths 
while on TPN were attributed to TPN complications (5–6% from sepsis or central-line sep-
sis and 6–9% from IFALD) [77]. A three-year prospective study reported 94 vs. 87% three-
year survival in TPN non-transplant candidates vs. TPN transplant candidates who did not 
undergo transplantation. In addition, the three-year survival was 89 vs. 85 vs. 70% for those 
having first SBTx vs. transplant candidates with central venous catheter complications vs. 
candidates with parenteral nutrition-related liver failure [78].
Intestinal Transplantation
http://dx.doi.org/10.5772/intechopen.74825
303
11. Quality of life
Quality of life plays an important role in the decision-making for ITx candidates. ITx patients 
have reported better fatigue, gastrointestinal symptoms, stoma management/bowel movements, 
ability to holiday/travel and global health/QoL and probably better eating ability but worse 
sleeping patterns [79]. Others have found that ITx recipients have similar QoL to those who are 
stable on TPN, but both are better than those with complicated intestinal failure on TPN [80].
12. Future perspectives
ITx and its secrets have not been deciphered yet. The main issue remains the challenging 
balance between appropriate immunosuppression and over-immunosuppression. Therefore, 
ITx teams have been trying to develop markers that will provide adequate warning in case of 
rejection [45].
Multivisceral organ transplantation may solidify its role in the treatment of slow-growing 
abdominal cancers that are deemed “non-resectable” [81–83].
Another challenge will be to understand the physiology of the transplanted small bowel, 
such as its altered microflora and altered motility. New research has suggested that the flora 
composition within the graft may be a risk factor for acute rejection when more immunogenic 
species predominate [84].
Tolerance remains the ‘Holy Grail’ of transplantation and is characterized by increased 
allograft survival in the absence of immunosuppression and absent or reduced donor-specific 
response. Groups have used donor-specific blood transfusion in order to induce tolerance by 
upregulating graft protective memory Tregs [85]. Also, centers have introduced experimental 
models to induce microchimerism and tolerance by transplanting bone marrow along with the 
intestinal allograft [86]. These protocols could allow for sufficient immunosuppression with 
lower doses of immunosuppressants. This ongoing research may change the future of ITx.
13. Conclusion(s)
ITx continues to evolve and graft survival rates are nowadays more comparable with the 
results of other solid organ transplants. The main challenge is to develop immunosuppression 
protocols that can ensure long-term intestine graft function and less infectious complications. 
When this is accomplished ITx could potentially change from being a life-saving treatment to 
becoming a realistic first-line therapy for IF.
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